Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.3K Buy
1,727
+215
+14% +$24.8K 0.23% 80
2025
Q4
$14.3K Sell
1,512
-15,889
-91% -$1.49M 0.26% 77
2025
Q3
$1.48M Buy
17,401
+2,000
+13% +$165K 0.21% 77
2025
Q2
$1.22M Sell
15,401
-11,547
-43% -$918K 0.16% 71
2025
Q1
$2.42M Buy
26,948
+6,902
+34% +$644K 0.44% 43
2024
Q4
$2.01M Buy
20,046
+7,795
+64% +$804K 0.36% 52
2024
Q3
$1.39M Sell
12,251
-265
-2% -$31.5K 0.28% 64
2024
Q2
$1.55M Sell
12,516
-1,784
-12% -$230K ﹤0.01% 79
2024
Q1
$1.89M Sell
14,300
-3,371
-19% -$416K 0.3% 69
2023
Q4
$1.93M Buy
+17,671
New +$1.83M 0.39% 53

Other funds holding MRK

LM Advisors's MRK Position: Q1 2026 in Review

LM Advisors increased its Merck (MRK) stake by 14% in Q1 2026, buying an estimated $24.8K and bringing the position to 1,727 shares worth $14.3K. The position accounts for 0.23% of the portfolio, ranked #80.

LM Advisors first reported a position in MRK in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.42M in Q1 2025. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • LM Advisors held 1,727 shares of Merck worth $14.3K as of Q1 2026.
  • LM Advisors bought 215 Merck shares in Q1 2026, an estimated $24.8K.
  • Merck made up 0.23% of LM Advisors's portfolio in Q1 2026, its #80 holding.
  • LM Advisors first reported a position in Merck in Q4 2023 and has held it in 10 quarters since.
  • LM Advisors's Merck position peaked at $2.42M in Q1 2025.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on LM Advisors's 13F filing for Q1 2026, filed 14 May 2026.